Vivo Leads the $25M Aerobiotix, Inc. Growth Equity Deal
Bolt Biotherapeutics strikes a major upsized $230M IPO for next-gen cancer work
Bolt Biotherapeutics strikes a major upsized $230M IPO [...]
Vivo Capital and an Investor Syndicate Completes Sale of Surgical Specialties Corporation to GTCR-backed Corza Health
Vivo Capital and an Investor Syndicate Completes Sale [...]
Vivo Capital’s Portfolio Company, Preventice was Bought by Boston Scientific for $1.2B
Vivo Capital's Portfolio Company, Preventice was Bought by [...]
-
Congratulations to Prof. Frances Arnold, the first American woman to win the Nobel Prize in Chemistry and co-founder of Vivo portfolio company Provivi, for her recent appoint as Co-Chair of President-elect Biden’s Council of Advisors on Science and Technology (PCAST)! GalleryCongratulations to Prof. Frances Arnold, the first American woman to win the Nobel Prize in Chemistry and co-founder of Vivo portfolio company Provivi, for her recent appoint as Co-Chair of President-elect Biden’s Council of Advisors on Science and Technology (PCAST)!
Congratulations to Prof. Frances Arnold, the first American woman to win the Nobel Prize in Chemistry and co-founder of Vivo portfolio company Provivi, for her recent appoint as Co-Chair of President-elect Biden’s Council of Advisors on Science and Technology (PCAST)!
Congratulations to Prof. Frances Arnold, the first [...]
Vivo Portfolio Company, Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARROTM) in Greater China
Vivo Portfolio Company, Aadi Bioscience and EOC Pharma [...]
Vivo Capital Appoints New Managing Partners and Partners
Vivo Capital Appoints New Managing Partners and PartnersJanuary [...]
-
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China Gallery
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
VISEN Pharmaceuticals Closes $150 Million Series B Financing [...]
Serán Bioscience Announces Investment by Vivo Capital
Serán Bioscience Announces Investment by Vivo Capital January [...]